Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Telacebec Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
Telacebec: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Vebicorvir Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
Vebicorvir: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Volixibat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
Volixibat: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Enoblituzumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
Enoblituzumab: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
FAM186A Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
4 August 2026
A visual target evaluation report for FAM186A, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
FAM185A Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
4 August 2026
A visual target evaluation report for FAM185A, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
FAM184B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
4 August 2026
A visual target evaluation report for FAM184B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
FAM184A Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
4 August 2026
A visual target evaluation report for FAM184A, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
FAM181B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
4 August 2026
A visual target evaluation report for FAM181B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
FAM181A Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
4 August 2026
A visual target evaluation report for FAM181A, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
FAM180B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
4 August 2026
A visual target evaluation report for FAM180B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
FAM180A Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
4 August 2026
A visual target evaluation report for FAM180A, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.